BRAF inhibitors by present standards are typically utilized in melanoma patients who are symptomatic due to high tumor burden, rather than in patients who achieve “no evidence of disease” status after surgical resection of an isolated metastasis. The gene discussed is BRAF; the disease is neoplasm.